HR+/HER2− metastatic BC has benefited from the emergence of molecularly targeted therapies, including CDK4/6 inhibitors (palbociclib, abemaciclib) and mTOR inhibitors (everolimus). This evidence concerns the gene MTOR and breast cancer.